|
Welcome to datamethods
|
|
1
|
13812
|
July 24, 2018
|
|
Thinking Clearly about Association Studies (Risk Factors and Causal Salad included)
|
|
29
|
310
|
April 7, 2026
|
|
Bayesian randomized non-inferiority trial design
|
|
1
|
57
|
April 4, 2026
|
|
Collider in RCT Subgroup Analysis
|
|
7
|
122
|
April 4, 2026
|
|
How can I communicate hazard ratios from log-transformed biomarkers in a clinically interpretable way?
|
|
4
|
81
|
April 3, 2026
|
|
Sample size in prognostic factor research
|
|
5
|
94
|
April 3, 2026
|
|
A/B Testing for Information Gain
|
|
1
|
42
|
April 2, 2026
|
|
Experimenting with a Bayesian Partial Proportional Odds Model
|
|
2
|
144
|
April 2, 2026
|
|
Decision Analysis in Clinical Guidelines: Net Benefit, NNT, & NRI
|
|
6
|
105
|
April 2, 2026
|
|
Sample size calculation for Paired Data using ordinal models
|
|
1
|
44
|
March 31, 2026
|
|
Is the use of conditional logistic regression necessary in case-control study？
|
|
7
|
128
|
March 31, 2026
|
|
Clustering in the denominator: non-independence of starts in racing fatality studies
|
|
4
|
120
|
March 31, 2026
|
|
Trying to understand statistical methods through the lens of replication
|
|
6
|
206
|
March 30, 2026
|
|
Biomarker evaluation - c-statistic (AUC) and alternatives
|
|
44
|
7644
|
March 30, 2026
|
|
Where are the exceptional responders?
|
|
9
|
1142
|
March 30, 2026
|
|
Best model reduction approach for Fine-Gray prediction model
|
|
5
|
73
|
March 27, 2026
|
|
Scoping review + SOCI: to assess DHIS2 applicability for NCD
|
|
2
|
55
|
March 26, 2026
|
|
Internal Validation with Bayesian models
|
|
6
|
65
|
March 25, 2026
|
|
Author Checklist
|
|
7
|
100892
|
March 24, 2026
|
|
Should one derive risk difference from the odds ratio?
|
|
622
|
79460
|
March 17, 2026
|
|
Statistics Agent Skills for Large Language Models
|
|
14
|
682
|
March 9, 2026
|
|
Estimand when treatment delays disease onset
|
|
4
|
121
|
March 5, 2026
|
|
My favorite distribution vandalized on Wikipedia
|
|
4
|
166
|
March 3, 2026
|
|
Generalizability vs. Transportability in Trials
|
|
61
|
1005
|
March 2, 2026
|
|
FDA Draft Guidance: Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products
|
|
10
|
733
|
March 2, 2026
|
|
Never seen this sort or primary endpoint and analysis in an RCT
|
|
17
|
314
|
February 27, 2026
|
|
Change the range not the language on confidence intervals
|
|
33
|
769
|
February 27, 2026
|
|
One-sided significance threshold of less than 0.1 in Phase 2 clinical trial
|
|
7
|
122
|
February 25, 2026
|
|
Narratively generative modeling
|
|
1
|
94
|
February 24, 2026
|
|
Six Entrenched Misconceptions About Meta-Analysis Models
|
|
4
|
218
|
February 22, 2026
|